Page 9 - DIAGEN

primeFISH Products Hermatology
HEMATOLOGY

PANEL

17-059 del 20q12-13

Chromosome 20q deletions can occur in a variety of my- approximately 2% of MDS cases. Patients with del (20q)
eloid disorders; for example, myelodysplastic syndromes base have an advantageous outcome compared to pa-
(MDS), acute myeloid leukemia (AML) and myeloprolifer tients with additional abnormalities such as del (5q), del
ative neoplasms (MPNs). in MDS, de1(20q) as the only (7q), monosomy 7 and trisomy 8. Most de1(20q) patients
cytogenetic abnormality is asso ciated with a favorable have intersti tial deletion between 20qll.2 and 20ql3.3.
prognosis, better survival, anda lower risk of conversion to
AML. De1(20q) with additional cytogenetic abnormalities
predicts a poor prognosis. The 20q deletion is seen in

TRANSLOCATION

SHGC-100713 D20S110
3' 5'
Gen Tel
PTPRT
NORMAL
20q12 515 kb
20q13.11-q13.12 RH65489 3' 5' SHGC-144461

Gen Tel
MYBL2
TRANSLOCATION
364 kb

(Not to scale)

TRANSLOCATION

References
Okada M, et al. (2012) Cancer Genet 205: 18-24.
Bacher U, et al. (2014) Br J Haematol 164: 822-33. www.diagen.com.tr
Liu et al., Cancer Genet Cytogenet. 2006 Nov;171(1):9-16
Douet-Gilbert et al (2008) Br J Haematol 143:716-720

info@diagen.com.tr PRODUCT CATALOGUE 9